Company Filing History:
Years Active: 2022
Title: Changjin Lee: Innovator in Targeted Pharmaceutical Preparations
Introduction
Changjin Lee is a prominent inventor based in Gangwon-do, South Korea. He has made significant contributions to the field of pharmaceutical preparations, particularly in the development of targeted drug delivery systems. His innovative work focuses on enhancing the therapeutic effects of anti-cancer medications.
Latest Patents
Changjin Lee holds a patent for a "Long-circulating liposome modified with c(RGD-ACP-K)." This invention pertains to the field of targeted pharmaceutical preparations. The long-circulating liposome is designed to deliver anti-cancer agents, such as doxorubicin, directly to tumor neovascular endothelial cells and tumor cells. This targeted approach not only prolongs the circulation time of the liposome in vivo but also enhances the overall therapeutic effect of anti-tumor medications. He has 1 patent to his name.
Career Highlights
Changjin Lee is associated with Beijing Greatsun Bto-pharm Technology Co., Ltd., where he continues to advance his research in pharmaceutical innovations. His work is pivotal in developing more effective cancer treatments through targeted delivery systems.
Collaborations
Some of his notable coworkers include Qiang Zhang and Cuishuan Wu, who contribute to the collaborative efforts in his research endeavors.
Conclusion
Changjin Lee's innovative work in the field of targeted pharmaceutical preparations exemplifies the potential of modern medicine to improve cancer treatment outcomes. His contributions are paving the way for more effective therapeutic strategies in oncology.